CoChat

Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Type I gastric carcinoids (TIGCs) are neuroendocrine neoplasms arising from enterochromaffin-like cells in atrophic body gastritis. Data regarding their evolution in prospective series are scarce, thus treatment and follow-up are not codified. Our aim was to evaluate clinical outcome and recurrence in TIGCs managed by endoscopic approach. METHODS: 33 patients (24 females; median age 65 years, range 23-81) were included and managed through endoscopic follow-up every 6-12 months, with lesion removal and multiple gastric biopsies. Baseline clinical and histological features were analyzed as risk factors by Cox regression. RESULTS: At diagnosis, 7 tumors were intramucosal carcinoids and 26 were polyps (median diameter 5 mm, range 2-20), multiple in 17 patients. Associated severe atrophy was present in 21 cases (63.6%), while mild atrophy was found in 6 cases (18.2%). During a 46-month median follow-up, survival was 100% and no metastases occurred. One patient developed a less-differentiated carcinoid that was radically treated by surgery. 21 patients (63.6%) had recurrence after a median of 8 months, 14 of these (66.6%) had a second recurrence after a median of 8 months following the previous carcinoid removal. Median recurrence-free survival was 24 months. Neither clinical nor biochemical recurrence-predicting factors were found. CONCLUSIONS: Although about 60% of TIGCs had recurrence after endoscopic resection, endoscopic management may be considered safe and effective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000329043

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 40

  1. Delle Fave G, Capurso G, Milione M, et al: Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol 2005; 19: 659- 673.
  2. Modlin IM, Lye KD, Kidd M: A 50-year anal- ysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99: 23-32.
  3. Yao JC, Hassan M, Phan A, et al: One hun- dred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
  4. Annibale B, Azzoni C, Corleto VD, et al: Atrophic body gastritis patients with entero- chromaffin-like cell dysplasia are at in- creased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepa- tol 2001; 13: 1449-1456.
  5. Rindi G, Azzoni C, La Rosa S, et al: ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evalu- ation by pathological analysis. Gastroenter- ology 1999; 116: 532-542.
  6. Solcia E, Bordi C, Creutzfeldt W, et al: Histo- pathological classification of nonantral gas- tric endocrine growths in man. Digestion 1998; 41: 185-200.
  7. Burkitt MD, Pritchard DM: Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006; 24: 1305-1320.
  8. Granberg D, Wilander E, Stridsberg M, et al: Clinical symptoms, hormone profiles, treat- ment, and prognosis in patients with gastric carcinoids. Gut 1998; 24: 223-228.
  9. Borch K, Ahrén B, Ahlman H, et al: Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242: 64-73.
  10. Gladdy RA, Strong VE, Coit D, et al: Defin- ing surgical indications for type I gastric car- cinoid tumor. Ann Surg Oncol 2009; 16: 3154-3160.
  11. Jordan PH Jr, Barroso A, Sweeney J: Gastric carcinoids in patients with hypergastrin- emia. J Am Coll Surg 2004; 199: 552-555.
  12. Rindi G, Bordi C, Rappel S, et al: Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20: 168-172.
  13. Landry CS, Brock G, Scoggins CR, et al: A proposed staging system for gastric carci- noid tumors based on an analysis of 1,543 patients. Ann Surg Oncol 2009; 16: 51-60.
  14. Schindl M, Kaserer K, Niederle B: Treatment of gastric neuroendocrine tumors: the neces- sity of a type-adapted treatment. Arch Surg 2001; 136: 49-54.
  15. Ichikawa J, Tanabe S, Koizumi W, et al: En- doscopic mucosal resection in the manage- ment of gastric carcinoid tumors. Endoscopy 2003; 35: 203-206.
  16. Hosokawa O, Kaizaki Y, Hattori M, et al: Long-term follow up of patients with multi- ple gastric carcinoids associated with type A gastritis. Gastric Cancer 2005; 8: 42-46.
  17. Modlin IM, Lye KD, Kidd M: Carcinoid tu- mors of the stomach. Surg Oncol 2003; 12: 153-172.
  18. D'Adda T, Annibale B, Delle Fave G, et al: Oxyntic endocrine cells of hypergastrinae- mic patients: differential response to antrec- tomy or octreotide. Gut 1996; 38: 668-674.
  19. Dakin GF, Warner RR, Pomp A, et al: Pre- sentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006; 93: 368-372.
  20. Campana D, Nori F, Pezzilli R, et al: Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 2008; 15: 337-342.
  21. Manfredi S, Pagenault M, de Lajarte-Thir- ouard AS, et al: Type 1 and 2 gastric carci- noid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur J Gastroenterol Hepatol 2007; 19: 1021-1025.
  22. Grozinsky-Glasberg S, Kaltsas G, Gur C, et al: Long-acting somatostatin analogues are an effective treatment for type 1 gastric car- cinoid tumours. Eur J Endocrinol 2008; 159: 475-482.
  23. Fykse V, Sandvik AK, Qvigstad G, et al: Treatment of ECL cell carcinoids with oc- treotide LAR. Scand J Gastroenterol 2004; 39: 621-628.
  24. Kokkola A, Sjöblom SM, Haapiainen R, et al: The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anae- mia: a prospective follow-up study. Scand J Gastroenterol 1998; 33: 88-92.
  25. Rappel S, Altendorf-Hofmann A, Stolte M: Prognosis of gastric carcinoid tumours. Di- gestion 1995; 56: 455-462.
  26. Annibale B, Marignani M, Azzoni C, et al: Atrophic body gastritis: distinct features as- sociated with Helicobacter pylori infection. Helicobacter 1997; 2: 57-64.
  27. Lahner E, Bordi C, Di Giulio E, et al: Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. Ali- ment Pharmacol Ther 2002; 16: 507-514.
  28. Bordi C, Azzoni C, Pilato FP, et al: Mor- phometry of gastric endocrine cells in hyper- gastrinemic patients treated with the soma- tostatin analogue octreotide. Regul Pept 1993; 47: 307-318.
  29. Peghini PL, Annibale B, Azzoni C, et al: Ef- fect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastro- enterology 2002; 123: 68-85.
  30. Berna MJ, Annibale B, Marignani M, et al: A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008; 93: 1582-1591.
  31. Dixon MF, Genta RM, Yardley JH, et al: Classification and grading of gastritis. The Updated Sydney System. International Workshop on the Histopathology of Gastri- tis, Houston 1994. Am J Surg Pathol 1996; 10: 1161-1181.
  32. Lahner E, Caruana P, D'Ambra G, et al: First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: when should it be done? Gastrointest Endosc 2001; 53: 443-448.
  33. Lahner E, Centanni M, Agnello G, et al: Oc- currence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis. Am J Med. 2008; 121: 136-141.
  34. Ruszniewski P, Delle Fave G, Cadiot G, et al: Well-differentiated gastric tumors/carcino- mas. Neuroendocrinology 2006; 84: 158-164.
  35. Johnson FE, Smith JB, Janney CM et al: Mul- tiple gastric carcinoids. J Am Coll Surg 2003; 196: 984-985.
  36. Hsing AW, Hansson LE, McLaughin JK, et al: Pernicious anemia and subsequent cancer: a population based cohort study. Cancer 1993; 71: 745-750.
  37. De Vries AC, Van Grieken NC, Looman CW, et al: Gastric cancer risk in patients with pre- malignant gastric lesions: a nationwide co- hort study in the Netherlands. Gastroenter- ology 2008; 134: 945-952.
  38. Bordi C, Azzoni C, Ferraro G, et al: Sam- pling strategies for analysis of enterochro- maffin-like cell changes in Zollinger-Elli- son Syndrome. Am J Clin Pathol 2000; 114: 419-425.
  39. 10.1210%2fjc.81.2.677 · doi:10.1210/jc.81.2.677
  40. 10.1210%2fjc.86.5.2236 · DOI

Cited by

Metadata

Authors
Merola, E., Sbrozzi-Vanni, A., Panzuto, F., D’Ambra, G., Di Giulio, E., Pilozzi, E., Capurso, G., Lahner, E., Bordi, C., Annibale, B., & Delle Fave, G.
Affiliations
  • Azienda Ospedaliera Sant'Andrea (IT)
  • University of Parma (IT)
Venue
Neuroendocrinology
Publisher
S. Karger AG
Published
2011-07-30
Volume
95
Issue
3
Pages
207-213
ISSN
  • 0028-3835 (ISSN-L)
  • 1423-0194
OpenAlex
W1970633635
Cited by
132
References
44
Citations by year
2026: 3 · 2025: 5 · 2024: 11 · 2023: 13 · 2022: 6 · 2021: 12 · 2020: 8 · 2019: 5 · 2018: 8 · 2017: 5 · 2016: 12 · 2015: 15 · 2014: 12 · 2013: 8 · 2012: 9
FWCI
6.96
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Neuroendocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • UnissResearch (Università degli Studi di Sassari) (submittedVersion)
Funders
Ministero dell'Università e della Ricerca
Topics
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
Keywords
enterochromaffin-like cells, neuroendocrine neoplasms, atrophic gastritis, endoscopic resection, tumor recurrence, recurrence-free survival, risk factors, gastric polyps
MeSH terms
Adult, Aged, Aged, 80 and over, Carcinoid Tumor, Endoscopy, Female, Follow-Up Studies, Gastritis, Atrophic, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Retrospective Studies, Risk Factors, Stomach Neoplasms, Survival Rate, Proportional Hazards Models, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.